UPDATE: SVB Leerink On Fate Price Target Trim: Sees Induced Pluripotent Stem Cell (iPSC)-Derived Cell Candidates FT596 & FT516 To Present At The American Society For Hematology On 12/13; Notes Increased Cash Burn With Est. At $210M In FY21 & $306M In FY22